查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
视网膜健康的全球市场:市场规模 - 各适应症，各治疗法，各流通管道，各地区展望，竞争策略，各市场区隔预测(～2032年)
市场调查报告书
商品编码
1170433

视网膜健康的全球市场:市场规模 - 各适应症，各治疗法，各流通管道，各地区展望，竞争策略，各市场区隔预测(～2032年)

Retina Health Market Size- By Disease Indication, By Treatment, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecasts to 2032
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 225 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球视网膜健康的市场规模，预计至2032年达到215亿9,000万美元，以7.8％的年复合成长率成长。

为了保持最佳的视网膜健康，提供各种治疗方法和药物，知道选项的人越多，产品的市场预计今后慢慢扩大。

北美市场，由于视网膜疾病高的发生率和该地区的主要企业的发展等要素，预计急速扩的。亚太地区市场，由于医疗基础设施的迅速扩大和平均每人的所得增加，预计大幅度扩大。

本报告提供全球视网膜健康市场相关调查，市场动态，市场变数与展望，各适应症、治疗方法、流通管道、地区的市场分析，企业简介等相关资讯。

目录

第1章 简介

  • 调查范围
  • 市场区隔分析

第2章 调查手法

  • 调查资料来源
  • 市场规模的估计
  • 资料的三角测量

第3章 摘要整理

第4章 市场动态

  • 促进因素，阻碍因素，机会，课题的分析
    • 促进因素
    • 阻碍因素
    • 机会
    • 课题
  • 全球视网膜健康市场上COVID-19的影响

第5章 市场变数与展望

  • SWOT分析
    • 优势
    • 弱点
    • 机会
    • 威胁
  • PESTEL分析
    • 政治形势
    • 经济形势
    • 社会形势
    • 技术形势
    • 环境形势
    • 法律上的形势
  • 波特的五力分析
    • 供给企业谈判力
    • 买方议价能力
    • 替代品的威胁
    • 新加入厂商的威胁
    • 竞争企业间的敌对关係
  • 热图分析

第6章 全球视网膜健康市场:各适应症(2019年～2032年(100万美元))

  • 老年性黄斑部病变(AMD)
  • 糖尿病视网膜病变
  • 遗传性视网膜疾病
  • 视网膜胚细胞瘤
  • 视网膜静脉阻塞症
  • 其他

第7章 全球视网膜健康市场:各治疗法(2019年～2032年(100万美元))

  • 药物
  • 治疗
  • 基因治疗
  • 营养疗法
  • 外科手术
  • 其他

第8章 全球视网膜健康市场:各流通管道(2019年～2032年(100万美元))

  • 医院药局
  • 零售药局
  • 其他

第9章 全球视网膜健康市场:各地区(2019年～2032年(100万美元))

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他的欧洲
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 其他的亚太地区
  • 南美
    • 巴西
    • 阿根廷
    • 其他的南美
  • 中东、非洲
    • 沙乌地阿拉伯王国
    • 阿拉伯联合大公国
    • 其他的中东、非洲

第10章 企业简介

  • Allergan PLC
    • 企业概要
    • 财务展望
    • 产品概要
    • 最近的开发
  • Applied Genetic Technologies Corporation
  • Gensight Biologics
  • Hemera Biosciences LLC
  • Mejragtx Ltd.
  • Novaritis AG
  • Oxford Biomedica PLC
  • Regenxbio Inc.
  • Santen Pharmaceutical Inc.
  • Spark Therapeutics Inc.
简介目录
Product Code: HLCA2219

Global Retina Health Market Overview:

According to SPER Market Research, the Global Retina Health Market is estimated to reach USD 21.59 billion by 2032 with a CAGR of 7.8%.

To create electrical signals from the light that enters the eye, the retina-a tiny layer situated at the back of the eyes-must first convert the light into those signals. Images are created by the brain after it has processed the impulses. A Healthy retina can help avoid blindness as well as several visual problems and impairments. The two most common retinal diseases, macular degeneration and diabetic retinopathy impact millions of people globally. A wide range of treatments and medications are available to guarantee optimal retina Health, and as more people become aware of these options, the market for these products will grow gradually in the years to come.

Impact of COVID-19 on the Global Retina Health Market:

The huge impact of COVID-19 pandemic has had several negative effects on people's Health all across the world. A substantial social and economic burden has been placed on individuals all across the world as a result of the aftermath. While big politicians are putting new frameworks into place and companies are embracing cutting-edge expansion methods to stay relevant, people are dealing with a variety of emotional anguish. The increase in instances has exacerbated emotional and financial problems, particularly for the elderly. The younger population has also been experiencing difficulties as a result of job losses and is choosing family care to deal with the effects. The development of a vaccine for COVID-19 is the main area of concentration, which diverts attention from other diseases.

Scope of the Report:

Report Metric Details:

  • Market size available for years: 2019-2032
  • Base year considered: 2021
  • Forecast period: 2022-2032
  • Segments covered: By Disease Indication, By Treatment, By Distribution Channel
  • Regions covered: North America, Europe, Asia Pacific, Latin America, Middle East and Africa
  • Companies Covered: Allergan PLC, Applied Genetic Technologies Corporation, Gensight Biologics, Hemera Biosciences LLC, Meiragtx Ltd., Novartis AG, Oxford Biomedica PLC, Regenxbio Inc., Santen Pharmaceuticals Inc., Spark Therapeutics Inc.

Global Retina Health Market Segmentation:

  • By Disease Indication: Based on the Disease Indication, Global Retina Health Market is segmented as; Age-Related Macular Degeneration, Diabetic Retinopathy, Diabetic Retinopathy, Inherited Retinal Diseases, Retinoblastoma, Retinal Vein Occlusion, Others.
  • By Treatment: Based on the Treatment, Global Retina Health Market is segmented as; Drugs, Therapy, Gene Therapy, Nutrition Therapy, Surgery, others.
  • By Distribution Channel: Based on the Distribution Channel, Global Retina Health Market is segmented as; Hospital Pharmacy, Retail Pharmacy, Others.
  • By Region: The North American retina Health market is anticipated to expand quickly due to a variety of driving factors, including the high incidence of retinal diseases and the development of key market companies in the region. Due to the rapidly expanding Healthcare infrastructure and growing per capita income, the Asia-Pacific retina Health market will also experience significant expansion. A substantial senior population and increased public awareness of eye Health will also contribute to the market expanding at a strong rate.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global Retina Health Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Retina Health Market, By Disease Indication, 2019-2032 (USD Million)

  • 6.1. Age-Related Macular Degeneration
  • 6.2. Diabetic Retinopathy
  • 6.3. Diabetic Retinopathy
  • 6.4. Inherited Retinal Diseases
  • 6.5. Retinoblastoma
  • 6.6. Retinal Vein Occlusion
  • 6.7. Others

7. Global Retina Health Market, By Treatment, 2019-2032 (USD Million)

  • 7.1. Drugs
  • 7.2. Therapy
  • 7.3. Gene Therapy
  • 7.4. Nutrition Therapy
  • 7.5. Surgery
  • 7.6. others

8. Global Retina Health Market, By Distribution Channel, 2019-2032 (USD Million)

  • 8.1. Hospital Pharmacy
  • 8.2. Retail Pharmacy
  • 8.3. Others

9. Global Retina Health Market, By Region, 2019-2032 (USD Million)

  • 9.1 North America
    • 9.1.1 United States
    • 9.1.2 Canada
    • 9.1.3 Mexico
  • 9.2 Europe
    • 9.2.1 Germany
    • 9.2.2 United Kingdom
    • 9.2.3 France
    • 9.2.4 Italy
    • 9.2.5 Spain
    • 9.2.6 Rest of Europe
  • 9.3 Asia-Pacific
    • 9.3.1 China
    • 9.3.2 Japan
    • 9.3.3 India
    • 9.3.4 Australia
    • 9.3.5 South Korea
    • 9.3.6 Rest of Asia-Pacific
  • 9.4 South America
    • 9.4.1 Brazil
    • 9.4.2 Argentina
    • 9.4.3 Rest of South America
  • 9.5 Middle East & Africa
    • 9.5.1 Kingdom of Saudi Arabia
    • 9.5.2 United Arab Emirates
    • 9.5.3 Rest of Middle East & Africa

10. Company Profiles

  • 10.1 Allergan PLC
    • 10.1.1 Company details
    • 10.1.2 Financial outlook
    • 10.1.3 Product summary
    • 10.1.4 Recent developments
  • 10.2 Applied Genetic Technologies Corporation
    • 10.2.1 Company details
    • 10.2.2 Financial outlook
    • 10.2.3 Product summary
    • 10.2.4 Recent developments
  • 10.3 Gensight Biologics
    • 10.3.1 Company details
    • 10.3.2 Financial outlook
    • 10.3.3 Product summary
    • 10.3.4 Recent developments
  • 10.4 Hemera Biosciences LLC
    • 10.4.1 Company details
    • 10.4.2 Financial outlook
    • 10.4.3 Product summary
    • 10.4.4 Recent developments
  • 10.5 Mejragtx Ltd.
    • 10.5.1 Company details
    • 10.5.2 Financial outlook
    • 10.5.3 Product summary
    • 10.5.4 Recent developments
  • 10.6 Novaritis AG
    • 10.6.1 Company details
    • 10.6.2 Financial outlook
    • 10.6.3 Product summary
    • 10.6.4 Recent developments
  • 10.7 Oxford Biomedica PLC
    • 10.7.1 Company details
    • 10.7.2 Financial outlook
    • 10.7.3 Product summary
    • 10.7.4 Recent developments
  • 10.8 Regenxbio Inc.
    • 10.8.1 Company details
    • 10.8.2 Financial outlook
    • 10.8.3 Product summary
    • 10.8.4 Recent developments
  • 10.9 Santen Pharmaceutical Inc.
    • 10.9.1 Company details
    • 10.9.2 Financial outlook
    • 10.9.3 Product summary
    • 10.9.4 Recent developments
  • 10.10 Spark Therapeutics Inc.
    • 10.10.1 Company details
    • 10.10.2 Financial outlook
    • 10.10.3 Product summary
    • 10.10.4 Recent developments